FDA, Lilly

Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,
FDA says knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow | After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound,
Eli Lilly Wants to Join Lawsuit Over Compounded Weight-Loss Drugs
The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it cannot rely on the FDA to protect it's interests.
Eli Lilly asks to join FDA in opposing lawsuit from pharmacies
CNBC's Becky Quick reports on news from Eli Lilly. Court throws out Biden FCC’s net neutrality rule 20 Incredible Cosplayers Who Nailed Their Characters Perfectly College football fans had jokes after Georgia's Parker Jones got a sideline penalty for colliding with a ref The 14 Things in Your Bathroom You Should Get Rid of Immediately Apple agrees to pay $95 million to settle Siri eavesdropping claims I’m a Retired Boomer: Here Are 6 Things I No Longer Buy Because They’re a Waste of Money Scientists discovered 50,
Pharma giant seeks to join lawsuit against FDA over weight loss drugs
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some pharmacies have practiced in mass-marketing copies of its highly popular GLP-1 medications.
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
FiercePharma1d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
and Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more cost ...
emjreviews.com19h
Could Eli Lilly take the crown in the obesity market?
According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.
Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients
The drug was launched in the U.S. back in 2023 to treat obesity.
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
The Financial Express3d
Eli Lilly’s Zepbound holds potential to dominate obesity market
Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...
Does This News From the FDA Make Eli Lilly a Buy for 2025?
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Why the Obesity Drug Revolution Is a Work in Progress
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...